Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus

Luo, Jianjun; Zhang, Zi-Han; Liu, Qingxin; Zhang, Wen; Wang, Jianhua; Yan, Zhenlin

doi:10.1007/s12072-015-9663-8

Cited by 66 publications

(78 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, low dose rate of radiation had been reported to decrease the incidence of metastasis by altering the immunophenotype of the tumor cells [27, 28]. Most importantly, EVBT and sequential 3-DCRT were capable of inhibiting MPVTT [14–16, 29]. However, MPVTT treated by these two different types of radiation had never been directly compared.…”

Section: Discussionmentioning

confidence: 99%

Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus

Zhang

Liu

et al. 2017

Oncotarget

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) patients with main portal vein tumor thrombus have a median survival time of only about 4 months. We therefore compared the safety and efficacy of endovascular brachytherapy (EVBT) and sequential three-dimensional conformal radiotherapy (3-DCRT). From a cohort of 176 patients, we treated 123 with EVBT using iodine-125 seed strands (group A) and the remaining 53 with sequential 3-DCRT (group B). Overall survival, progression free survival and stent patency characteristics were compared between the two groups. Our analysis demonstrated a median survival of 11.7 ± 1.2 months in group A versus 9.5 ± 1.8 months in group B (p = 0.002). The median progression free survival was 5.3 ± 0.7 months in groupA versus 4.4 ± 0.4 months in group B (p = 0.010). The median stent patency period was 10.3 ± 1.1 months in group A versus 8.7 ± 0.7 months in group B (p = 0.003). Therefore, as compared to sequential 3-DCRT, EVBT combined with portal vein stenting and TACE improved overall survival of HCC patients with main portal vein tumor thrombus.

show abstract

Section: Discussionmentioning

confidence: 99%

Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus

Zhang

Liu

et al. 2017

Oncotarget

Self Cite

View full text Add to dashboard Cite

show abstract

“…Many clinical researches have reported that IRT was suitable for the treatment of pancreatic cancer. [ 28–34 ] Hence, to investigate the effect of CIRT for pancreatic cancer, we adopted human pancreatic cancer (SW1990) cells for all experiments in vitro. First, as sufficient intracellular accumulation of NPs is a prerequisite for an effective treatment, the cellular uptake and intracellular distribution of TiO 2 ‐tyr was visualized via biological TEM (bio‐TEM).…”

Section: Methodsmentioning

confidence: 99%

Auger Electrons Constructed Active Sites on Nanocatalysts for Catalytic Internal Radiotherapy

Wang

et al. 2020

Advanced Science

View full text Add to dashboard Cite

Excess electrons play important roles for the construction of superficial active sites on nanocatalysts. However, providing excess electrons to nanocatalysts in vivo is still a challenge, which limits the applications of nanocatalysts in biomedicine. Herein, auger electrons (AEs) emitted from radionuclide 125 (125I) are used in situ to construct active sites in a nanocatalyst (TiO2) and the application of this method is further extended to cancer catalytic internal radiotherapy (CIRT). The obtained 125I‐TiO2 nanoparticles first construct superficial Ti3+ active sites via the reaction between Ti4+ and AEs. Then Ti3+ stretches and weakens the OH bond of the absorbed H2O, thus enhancing the radiolysis of H2O molecules and generating hydroxyl radicals (•OH). All in vitro and in vivo results demonstrate a good CIRT performance. These findings will broaden the application of radionuclides and introduce new perspectives to nanomedicine.

show abstract

“…On the other hand, the portal vein pressure is rising with development of PVTT, which increases the risk of esophageal and gastric bleeding and indirectly leads to death [11]. Therefore, opening the occlusion of the portal vein caused by PVTT and reperfusing the portal vein could improve the success of TACE, and this could be achieved using portal vein stenting (PVS) [12–14]. PVS combined with TACE has been successfully used in the treatment of HCC with PVTT [6].…”

Section: Introductionmentioning

confidence: 99%

Portal Vein Stenting Combined with Iodine-125 Seeds Endovascular Implantation Followed by Transcatheter Arterial Chemoembolization for Treatment of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus

Sun

Zhou

Zhu

et al. 2016

BioMed Research International

View full text Add to dashboard Cite

Aim was to assess the therapeutic value of portal vein stenting (PVS) combined with iodine-125 seed (125I seed) strand endovascular implantation followed by transcatheter arterial chemoembolization (TACE) for treating patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). This was a retrospective study of 34 patients aged 29–81 years, diagnosed HCC with PVTT, and treated with PVS combined with 125I seed strand endovascular implantation followed by TACE between January 2012 and August 2014. Survival, stent patency, technical success rate, complications related to the procedure, and adverse events were recorded. The technical success rate was 100%. No serious procedure-related adverse event was recorded. The median survival was 147 days. The cumulative survival rates and stent patency rates at 90, 180, and 360 days were 94.1%, 61.8%, and 32.4% and 97.1% (33/34), 76.9% (24/34), and 29.4% (10/34), respectively. PVS combined with 125I seed strand endovascular implantation followed by TACE is feasible for patients with HCC and PVTT. It resulted in appropriate survival and stent patency, with no procedure-related adverse effects.

show abstract

Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus

Abstract: These findings suggested that EVBT combined with stent placement and TACE might be a safe and effective palliative treatment option for HCC with main portal vein tumor thrombus.

Cited by 66 publications

References 24 publications

Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus

Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus

Auger Electrons Constructed Active Sites on Nanocatalysts for Catalytic Internal Radiotherapy

Portal Vein Stenting Combined with Iodine-125 Seeds Endovascular Implantation Followed by Transcatheter Arterial Chemoembolization for Treatment of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus

Contact Info

Product

Resources

About